Inhibikase Therapeutics
IKT2.2602.26% ( +0.050 )
Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, w...
- Open
- 2.210
- High
- 2.280
- Low
- 2.185
- Prev. Close
- 2.210
- Volume
- 143.34K
- Turnover
- 321.44K
- Avg Price
- 2.243
- Bid/Ask Ratio
- --
- Amplitude
- 4.30%
- 52wk High
- 2.530
- Volume Ratio
- 0.30
- Turnover Ratio
- 0.30%
Inhibikase Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 13, 2026Price forecast
$6.00165.49%
Forecast & RatingStrong buy
9analysts
- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 19 hours ago
Inhibikase swaps 18,030,000 shares for RA Capital pre-funded warrant in unregistered offering
- rttnews · Jul 27 at 05:33 AM
Biotech Stocks At 52-Week Highs- IKT, HALO, JAZZ, CORT, LQDA
- PUBT · Jul 23 at 07:07 AM
Inhibikase wins FDA orphan drug designation for IKT-001 in PAH
- PUBT · Jul 17 at 04:55 PM
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics
- Tip Ranks · Jul 15 at 03:05 AM
Inhibikase raises $50M to fund PAH program
- rttnews · Jul 15 at 02:55 AM
Biotech Stocks Hit 52-Week Highs - TOI, IKT, ANRO, ELV, PRVA
